MAPT and Alzheimer disease: The Alzheimer’s continuum group and AD group showed lower CSF levels of Aβ42 (p < 0.001, p < 0.001) and higher CSF levels of T-tau (p < 0.001, p < 0.001), P-tau181 (p < 0.001, p < 0.001), T-tau/Aβ42 ratios (p < 0.001, p < 0.001), and P-tau181/Aβ42 ratios (p < 0.001, p < 0.001) than non-AD (Table 1).